Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 05, 2024 05:27 ET | Source: Curium

Curium Adds the Institut Laue-Langevin Reactor to Global Irradiation Portfolio to Ensure Continuous Supply of Lutetium-177 to Benefit More Than 100,000 Cancer Patients Over the Next 5 Years

Curium partners with Institut Laue–Langevin to enhance Lutetium-177 supply, benefiting over 100,000 cancer patients in five years.
May 30, 2024 03:00 ET | Source: Curium US LLC

Curium annonce les premieres doses commerciales en France de PYLCLARI® - un traceur PET innovant 18F-PSMA indique dans le cancer de la prostate

PARIS, 30 mai 2024 (GLOBE NEWSWIRE) -- Curium, leader mondial de la médecine nucléaire, annonce aujourd'hui que suite à la Publication au Journal Officiel du 2 mai, , les patients français ont reçu...
May 30, 2024 03:00 ET | Source: Curium

Curium Announces First Commercial Doses in France of Pylclari® – an Innovative 18F-Psma Pet Tracer Indicated in Patients With Prostate Cancer

first doses of PYLCLARI in France for prostate cancer patients
May 29, 2024 03:32 ET | Source: Curium

Curium Extends Irradiation Partnership With NRG I PALLAS in Netherlands for Continuous Supply of Lutetium-177 to Treat 1,000s of Cancer Patients Each Year

PARIS, May 29, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that it has signed a long-term agreement to extend its current partnership with NRG I PALLAS for...
May 06, 2024 04:25 ET | Source: Curium

Curium Announces First Commercial Doses in Germany of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer

Curium announced that today in Munich and Nurnberg, Germany the first commercial doses of PYLCLARI® have been delivered.
May 06, 2024 04:25 ET | Source: Curium

Curium: Erste Kommerzielle Dosen von PYLCLARI® in Deutschland Verfügbar - Ein Innovativer 18f-PSMA PET Tracer für Patienten Mit Prostatakrebs

PARIS, May 06, 2024 (GLOBE NEWSWIRE) -- Curium, ein weltweit führendes Unternehmen der Nuklearmedizin, gab heute bekannt, dass in München und Nürnberg die ersten kommerziellen Dosen von PYLCLARI®...
April 23, 2024 00:01 ET | Source: Curium

Curium Enrolls First Prostate Cancer Patients in its Phase 3 SOLAR Trials

patient enrollment in clinical trial
April 09, 2024 08:50 ET | Source: Curium

Curium Announces First Commercial Dose in the Netherlands of PYLCLARI® – an Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer

Curium proudly introduces the first commercial dose of PYLCLARI® in the Netherlands, revolutionizing prostate cancer diagnosis. This innovative 18F-PSMA PE
April 09, 2024 04:13 ET | Source: Curium US LLC

Curium prévoit d’augmenter considérablement sa capacité de production de lutécium-177 et son empreinte PET grâce à l’acquisition d’Eczacibaşi-Monrol

Le projet d’acquisition d’Eczacıbaşı-Monrol va : Tirer parti de l’actuel partenariat dans le domaine du Lu-177 pour donner naissance à un fabricant de premier plan de cet isotopeAjouter 12 sites...
April 09, 2024 04:13 ET | Source: Curium

Curium plant mit der Vereinbarung zur Übernahme von Eczacıbaşı-Monrol eine erhebliche Ausweitung der Lutetium-177-Kapazitäten und der Präsenz im PET-Bereich

Die geplante Übernahme von Eczacıbaşı-Monrol soll Folgendes erreichen: Ausbau der bestehenden Partnerschaft im Bereich Lu-177, um führender Hersteller des Isotops zu werdenErweiterung des bestehenden...